The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of ERCC1 (rs11615) and DNASE2B (rs3738573) polymorphisms with pathologic complete response to neoadjuvant chemotherapy for HER2-overexpressing breast cancer.
Agnes Ducoulombier
No relevant relationships to disclose
Aurelie Dumont
No relevant relationships to disclose
Emmanuelle Tresch
No relevant relationships to disclose
Jinying Chen
No relevant relationships to disclose
Diane Pannier
No relevant relationships to disclose
Francoise Revillion
No relevant relationships to disclose
Jacques Bonneterre
No relevant relationships to disclose
Jean-Philippe Peyrat
No relevant relationships to disclose